Selected research
Industry Growth & Trends
Global CD14 Antibody Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global CD14 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for CD14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for CD14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for CD14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the CD14 Antibody market include Thermo Fisher Scientific, Merck, Boster Biological Technology, Santa Cruz Biotechnology, NSJ Bioreagents, Miltenyi Biotec, Leinco Technologies, FineTest and EXBIO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global CD14 Antibody market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The CD14 Antibody market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CD14 Antibody market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CD14 Antibody.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global CD14 Antibody market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
CD14 Antibody Market by Company
Thermo Fisher Scientific
Merck
Boster Biological Technology
Santa Cruz Biotechnology
NSJ Bioreagents
Miltenyi Biotec
Leinco Technologies
FineTest
EXBIO
Everest Biotech
Bio-Rad
BioLegend
Beckman Coulter
Atlas Antibodies
CD14 Antibody Segment by Type
Polyclonal
Monoclonal
CD14 Antibody Segment by Application
Immunohistochemistry Paraffin
Immunohistochemistry Frozen
Flow Cytometry
Others
CD14 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD14 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CD14 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD14 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of CD14 Antibody companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Immunohistochemistry Paraffin
- Immunohistochemistry Frozen
- Flow Cytometry
- Others
Companies covered
- Thermo Fisher Scientific
- Merck
- Boster Biological Technology
- Santa Cruz Biotechnology
- NSJ Bioreagents
- Miltenyi Biotec
- Leinco Technologies
- FineTest
- EXBIO
- Everest Biotech
- Bio-Rad
- BioLegend
- Beckman Coulter
- Atlas Antibodies
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global CD14 Antibody Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global CD14 Antibody Market Size by Region (2021-2032)
- 1.4.1 Global CD14 Antibody Market Size by Region (2021-2026)
- 1.4.2 Global CD14 Antibody Market Size by Region (2027-2032)
- 1.5 Key Regions CD14 Antibody Market Size (2021-2032)
- 1.5.1 North America CD14 Antibody Market Size Growth Rate (2021-2032)
- 1.5.2 Europe CD14 Antibody Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific CD14 Antibody Market Size Growth Rate (2021-2032)
- 1.5.4 South America CD14 Antibody Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa CD14 Antibody Market Size Growth Rate (2021-2032)
2 CD14 Antibody Market by Type
- 2.1 Type Introduction
- 2.1.1 Polyclonal
- 2.1.2 Monoclonal
- 2.2 Global CD14 Antibody Market Size by Type
- 2.2.1 Global CD14 Antibody Market Size Overview by Type (2021-2032)
- 2.2.2 Global CD14 Antibody Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global CD14 Antibody Market Size Forecasted by Type (2027-2032)
- 2.3 Global CD14 Antibody Market Size by Regions
- 2.3.1 North America CD14 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe CD14 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific CD14 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America CD14 Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa CD14 Antibody Market Size Breakdown by Type (2021-2026)
3 CD14 Antibody Market by Application
- 3.1 Type Introduction
- 3.1.1 Immunohistochemistry Paraffin
- 3.1.2 Immunohistochemistry Frozen
- 3.1.3 Flow Cytometry
- 3.1.4 Others
- 3.2 Global CD14 Antibody Market Size by Application
- 3.2.1 Global CD14 Antibody Market Size Overview by Application (2021-2032)
- 3.2.2 Global CD14 Antibody Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global CD14 Antibody Market Size Forecasted by Application (2027-2032)
- 3.3 Global CD14 Antibody Market Size by Regions
- 3.3.1 North America CD14 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe CD14 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific CD14 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America CD14 Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa CD14 Antibody Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 CD14 Antibody Industry Trends
- 4.2 CD14 Antibody Industry Drivers
- 4.3 CD14 Antibody Industry Opportunities and Challenges
- 4.4 CD14 Antibody Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by CD14 Antibody Revenue (2021-2026)
- 5.2 Global CD14 Antibody Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global CD14 Antibody Key Company Headquarters & Area Served
- 5.4 Global CD14 Antibody Company, Product Type & Application
- 5.5 Global CD14 Antibody Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global CD14 Antibody Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 CD14 Antibody Players Market Share by Revenue in 2025
- 5.6.3 2025 CD14 Antibody Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Thermo Fisher Scientific
- 6.1.1 Thermo Fisher Scientific Company Information
- 6.1.2 Thermo Fisher Scientific Business Overview
- 6.1.3 Thermo Fisher Scientific CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Thermo Fisher Scientific CD14 Antibody Product Portfolio
- 6.1.5 Thermo Fisher Scientific Recent Developments
- 6.2 Merck
- 6.2.1 Merck Company Information
- 6.2.2 Merck Business Overview
- 6.2.3 Merck CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Merck CD14 Antibody Product Portfolio
- 6.2.5 Merck Recent Developments
- 6.3 Boster Biological Technology
- 6.3.1 Boster Biological Technology Company Information
- 6.3.2 Boster Biological Technology Business Overview
- 6.3.3 Boster Biological Technology CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Boster Biological Technology CD14 Antibody Product Portfolio
- 6.3.5 Boster Biological Technology Recent Developments
- 6.4 Santa Cruz Biotechnology
- 6.4.1 Santa Cruz Biotechnology Company Information
- 6.4.2 Santa Cruz Biotechnology Business Overview
- 6.4.3 Santa Cruz Biotechnology CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Santa Cruz Biotechnology CD14 Antibody Product Portfolio
- 6.4.5 Santa Cruz Biotechnology Recent Developments
- 6.5 NSJ Bioreagents
- 6.5.1 NSJ Bioreagents Company Information
- 6.5.2 NSJ Bioreagents Business Overview
- 6.5.3 NSJ Bioreagents CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 NSJ Bioreagents CD14 Antibody Product Portfolio
- 6.5.5 NSJ Bioreagents Recent Developments
- 6.6 Miltenyi Biotec
- 6.6.1 Miltenyi Biotec Company Information
- 6.6.2 Miltenyi Biotec Business Overview
- 6.6.3 Miltenyi Biotec CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Miltenyi Biotec CD14 Antibody Product Portfolio
- 6.6.5 Miltenyi Biotec Recent Developments
- 6.7 Leinco Technologies
- 6.7.1 Leinco Technologies Company Information
- 6.7.2 Leinco Technologies Business Overview
- 6.7.3 Leinco Technologies CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Leinco Technologies CD14 Antibody Product Portfolio
- 6.7.5 Leinco Technologies Recent Developments
- 6.8 FineTest
- 6.8.1 FineTest Company Information
- 6.8.2 FineTest Business Overview
- 6.8.3 FineTest CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 FineTest CD14 Antibody Product Portfolio
- 6.8.5 FineTest Recent Developments
- 6.9 EXBIO
- 6.9.1 EXBIO Company Information
- 6.9.2 EXBIO Business Overview
- 6.9.3 EXBIO CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 EXBIO CD14 Antibody Product Portfolio
- 6.9.5 EXBIO Recent Developments
- 6.10 Everest Biotech
- 6.10.1 Everest Biotech Company Information
- 6.10.2 Everest Biotech Business Overview
- 6.10.3 Everest Biotech CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Everest Biotech CD14 Antibody Product Portfolio
- 6.10.5 Everest Biotech Recent Developments
- 6.11 Bio-Rad
- 6.11.1 Bio-Rad Company Information
- 6.11.2 Bio-Rad Business Overview
- 6.11.3 Bio-Rad CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Bio-Rad CD14 Antibody Product Portfolio
- 6.11.5 Bio-Rad Recent Developments
- 6.12 BioLegend
- 6.12.1 BioLegend Company Information
- 6.12.2 BioLegend Business Overview
- 6.12.3 BioLegend CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 BioLegend CD14 Antibody Product Portfolio
- 6.12.5 BioLegend Recent Developments
- 6.13 Beckman Coulter
- 6.13.1 Beckman Coulter Company Information
- 6.13.2 Beckman Coulter Business Overview
- 6.13.3 Beckman Coulter CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Beckman Coulter CD14 Antibody Product Portfolio
- 6.13.5 Beckman Coulter Recent Developments
- 6.14 Atlas Antibodies
- 6.14.1 Atlas Antibodies Company Information
- 6.14.2 Atlas Antibodies Business Overview
- 6.14.3 Atlas Antibodies CD14 Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Atlas Antibodies CD14 Antibody Product Portfolio
- 6.14.5 Atlas Antibodies Recent Developments
7 North America
- 7.1 North America CD14 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America CD14 Antibody Market Size by Country (2021-2026)
- 7.3 North America CD14 Antibody Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe CD14 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe CD14 Antibody Market Size by Country (2021-2026)
- 8.3 Europe CD14 Antibody Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific CD14 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific CD14 Antibody Market Size by Country (2021-2026)
- 9.3 Asia-Pacific CD14 Antibody Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America CD14 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America CD14 Antibody Market Size by Country (2021-2026)
- 10.3 South America CD14 Antibody Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa CD14 Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa CD14 Antibody Market Size by Country (2021-2026)
- 11.3 Middle East & Africa CD14 Antibody Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst